Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XENON XE 133 vs TAUVID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.
Pulmonary ventilation imaging (FDA approved),Regional cerebral blood flow evaluation (FDA approved)
PET imaging of tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease
5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.
18 mg intravenously once daily.
Terminal elimination half-life: 1.5–2 minutes (fast washout from well-perfused tissues); total-body elimination half-life approximately 5–7 minutes due to slow release from adipose tissue. Clinical context: rapid clearance allows repeated imaging within short intervals.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals; may be prolonged in patients with renal impairment.
Xenon Xe 133 is inert and not metabolized; it is eliminated unchanged via exhalation.
Not metabolized; eliminated primarily by renal excretion as intact drug
Primarily eliminated via exhalation through the lungs (>95% unchanged); minimal renal excretion (<5% as dissolved gas).
Primarily renal excretion as unchanged drug (approximately 70%) with biliary/fecal elimination accounting for about 20-30%.
Negligible (<5%); Xenon is a noble gas and does not bind appreciably to plasma proteins.
Approximately 85-90% bound to serum albumin and alpha-1-acid glycoprotein.
Volume of distribution: 13–15 L/kg (large due to high lipid solubility, extensive distribution into fat and other tissues). Clinical meaning: indicates rapid and widespread tissue uptake, with adipose tissue as a slow-release reservoir.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Inhalation: near 100% (gas is fully absorbed from alveoli into the bloodstream; intravenous injection not used clinically).
Subcutaneous bioavailability is approximately 60-70% relative to intravenous administration.
No dose adjustment required; xenon is eliminated via exhalation.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required; xenon elimination is independent of hepatic function.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
0.1-0.3 m Ci/kg (3.7-11.1 MBq/kg) inhaled or intravenous, minimum 2 m Ci (74 MBq), maximum 10 m Ci (370 MBq).
Not approved for pediatric use; safety and efficacy not established.
Use lowest effective dose; consider reduced respiratory function but no specific dose adjustment required.
No specific dose adjustment recommended; use standard adult dosing.
None.
None
Radiation exposure risk; minimize dose and duration.,Use with caution in patients with impaired pulmonary function.,Pregnancy category C; use only if benefit outweighs risk.,Lactation: discontinue nursing or drug.,Ensure adequate ventilation to prevent accumulation of exhaled gas.
Image interpretation errors due to presence of non-specific binding or off-target uptake,Risk of misdiagnosis if used as a sole diagnostic tool,Radiation exposure risk; drug is radioactive
None specifically documented; contraindicated in patients with known hypersensitivity to xenon or components.
Known hypersensitivity to flortaucipir or any excipient
No food or drug interactions; no dietary restrictions required with Xenon Xe 133.
No specific food interactions. Patients should avoid caffeine and alcohol for 24 hours prior to the scan as they may affect brain activity, though not specifically contraindicated. Maintain normal diet but avoid heavy meals immediately before the procedure.
Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first trimester). Use only if benefit outweighs risk. Second and third trimester risk is lower but consider fetal radiation exposure.
FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequate human studies exist. First trimester: theoretical risk of fetal radiation exposure (estimated fetal absorbed dose <1 m Gy from a single administration), considered minimal. Second/third trimester: radiation risk similar; no known teratogenic effects. Overall, risk is low but exposure should be avoided unless benefit clearly outweighs risk.
No data on excretion in breast milk. Discontinue breastfeeding temporarily after administration. Advise pump and discard milk for at least 24 hours post-exposure. M/P ratio unknown.
No data on excretion into human milk. M/P ratio unknown. Due to short physical half-life (110 minutes) and low administered activity, breastfeeding interruption of 4 hours (10 half-lives) is recommended to minimize infant radiation exposure. Alternatively, pump and discard for 4 hours post-injection.
No dose adjustment is recommended based on pharmacokinetic changes; however, consider minimizing fetal radiation exposure by using lowest effective dose and shortest scan time.
No dosing adjustment needed. The administered activity (370 MBq ±10%) is fixed; no pharmacokinetic changes in pregnancy necessitate dose alteration.
Xenon Xe 133 is a radiopharmaceutical gas used for pulmonary ventilation scintigraphy. Its short half-life (5.24 days) allows for serial studies with minimal radiation exposure. Ensure patient has not recently undergone other nuclear medicine studies to avoid interference. Administer via closed breathing system to prevent environmental contamination. Image acquisition typically during equilibrium and washout phases. Adverse effects are rare but include dizziness, headache, or metallic taste.
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent indicated for PET imaging of tau pathology in patients with cognitive impairment being evaluated for Alzheimer's disease. Administer intravenously as a bolus injection (10 m Ci, 370 MBq). Image acquisition should begin approximately 80 minutes post-injection. False positives may occur in patients with prior strokes, brain tumors, or other causes of tau deposition. Do not use for screening or early-stage disease without cognitive symptoms. Ensure patient is well hydrated before administration. The effective radiation dose is about 7 m Sv.
This is a radioactive gas used to image lung function.,You will inhale the gas through a mouthpiece or mask while lying under a camera.,The amount of radiation is very low and considered safe.,No special precautions are needed after the test; you can resume normal activities.,Drink plenty of fluids after the test unless instructed otherwise.
TAUVID is a radioactive tracer used to detect tau protein tangles in the brain, which are associated with Alzheimer's disease.,You will receive a single injection into a vein. The scan will start about 80 minutes after the injection and lasts approximately 30 minutes.,Drink plenty of water before the procedure to help eliminate the radioactive material from your body.,You may experience mild discomfort at the injection site, but serious side effects are rare.,The amount of radiation exposure is low and similar to other diagnostic imaging procedures, but inform your doctor if you are pregnant or breastfeeding.,Results do not provide a definitive diagnosis but help your doctor evaluate your condition.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XENON XE 133 vs TAUVID, answered by our medical review team.
XENON XE 133 is a Radiopharmaceutical Diagnostic Agent that works by Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.. TAUVID is a Radiopharmaceutical Diagnostic Agent that works by TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XENON XE 133 and TAUVID depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XENON XE 133 is: 5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.. The standard adult dose of TAUVID is: 18 mg intravenously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XENON XE 133 and TAUVID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XENON XE 133 is classified as Category C. Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first . TAUVID is classified as Category C. FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.